Chlorhexidine and nystatin in the treatment of oral candidosis - a pilot study
- Conditions
- oral candidosisTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Registration Number
- EUCTR2016-005027-81-FI
- Lead Sponsor
- Maria Siponen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 40
Oral candidosis diagnosed with oral swab
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20
Age under 18, pregnancy or planning pregnancy, allergy to chlorhexidine, nystatin or additional ingredients of the study products, hereditary fructose-intolerance, fructose-intolerance, glucose-galactose absorption disorder, or saccarose-isomaltase deficiency, oral mucosal disease such as lichen planus or mucous membrane pemphigoid with severe symptoms, immunosuppressive condition such as untreated HIV-infection, on-going treatment for cancer, systemic immunosuppressive medication, desinfectant oral rinse or yeast infection medication used during the last four weeks.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To examine the use of chlorhexidine in the treatment of oral candidosis;Secondary Objective: To study the different diagnostic methods of oral candidosis and to study the salivary metabolites in oral candidosis;Primary end point(s): not/applicaple;Timepoint(s) of evaluation of this end point: not/applicaple
- Secondary Outcome Measures
Name Time Method Secondary end point(s): not/applicaple;Timepoint(s) of evaluation of this end point: not/applicaple